Breaking News
Get 50% Off 0
Last Call 🚨 SAVE on InvestingPro
Get 50% Off
Close

Athira Pharma Inc (ATHA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Athira Pharma's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.404 -0.001    -0.27%
20:23:45 - Real-time Cboe. Currency in USD
Type:  Equity
Market:  United States
  • Volume: 61,983
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.390 - 0.405
Athira Pharma 0.404 -0.001 -0.27%

Athira Pharma Inc Company Profile

 
Get an in-depth profile of Athira Pharma Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

26

Equity Type

ORD

Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Contact Information

Address 18706 North Creek Parkway Suite 104
Bothell, 98011
United States
Phone 425 620 8501
Fax -

Top Executives

Name Age Since Title
Kelly A. Romano 60 2020 Independent Chairwoman of the Board
Mark J. Litton 55 2019 President, CEO & Director
Anton P. Porsteinsson - 2022 Member of Scientific Advisory Board
John Olichney - 2022 Member of Scientific Advisory Board
James A. Johnson 67 2020 Independent Director
Barbara A. Kosacz 66 2021 Independent Director
Pierre N. Tariot - 2022 Member of Scientific Advisory Board
Paul Winner - 2022 Member of Scientific Advisory Board
John M. Fluke 81 2014 Independent Director
Joseph Eric Edelman 68 2020 Independent Director
Grant E. Pickering 56 2022 Independent Director
Michael A. Panzara 57 2022 Independent Director
Marwan Noel Sabbagh 58 2022 Member of Scientific Advisory Board
Hans Moebius 67 2019 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ATHA Comments

Write your thoughts about Athira Pharma Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email